Empowering physicians with ‘Physics’ to see standard medical images differently !
QuantMD, LLC is a Pittsburgh based healthcare diagnostics company with a global outreach servicing cutting-edge proprietary Healthcare Enhancement through Robust Algorithmic Diagnosis (HERALD) of medical images, for early and non-invasive cardiovascular disease diagnostics, surgical planning and interventional guidance. We service subscription based enhanced diagnostic value over a geographically unlimited territory using a cloud-enabled platform enabling an Expertise Amplification StrategY through Remote NEtworked Workflow: EASY-RENEW. The following video prepared in collaboration with our data warehousing partners, Management Science Associates Inc., provides an overview of our current offerings:
An older but technologically relevant 5-minute video overview from October 2012, presented by CEO, Prahlad G Menon during his graduate student days, goes over few of QuantMD's many competencies paving the way to the future of physics enabled medical imaging for better informed healthcare delivery:
QuantMD, LLC: i6 Demo Day 2012
We have patented cardiac MRI technology dedicated to diagnosing coronary heart disease (CHD) at the earliest possible stage through a proprietary imaging service.Our suite of high quality quantitative analytics forcardiac structure, function and perfusion from 3D and 4D contrast enhanced cardiac imaging identifies early signs of disease long before the patient experiences a major adverse cardiac event (MACE).
We also have patented image analytics technology for patient selection and optimization of cardiac resynchronization therapy (CRT) or pacemaker lead guidance. The QuantMD techniques have seen application to guiding appropriate treatment option selection while mitigating unnecessary risky and expensive interventional exams, as well as surgical planning and real-time guidance for interventional cardiology procedures including pacemaker lead implantation, ablations and renal denervation. More recently, we have begun servicing physics based surgical planning solutions for open heart procedures including surgical ventricular restoration (SVR), the Fontan surgery, amongst other non-cardiology applications in therapies targeting cancerous tumors in stereotactic radiosurgery. QuantMD is part of Carnegie Mellon University's Project Olympus program and seeks to transform its ground-breaking research in cardiac imaging into cutting edge technology that will revolutionize the healthcare industry.
The technology that forms the core of our business is one that
addresses the leading cause of death for both men and women in the
United States today i.e. cardiac disease. In 2006, 631,636 people died
of heart disease and heart disease caused 26% of deaths—more than one in
every four—in the United States. Every year about 785,000 Americans
have a first heart attack and other 470,000 who already had one or more
heart attacks have another attack. Coronary heart disease is the most
common type of heart disease and in 2005, 445,687 people died from
coronary heart disease. The worrying news is that heart disease is on the rise. According to the latest statistics, now 1 in 3 Americans (36.9%) have some form of heart disease, including high blood pressure, coronary heart disease, heart failure, stroke and other conditions. By 2030, approximately 116 million people in the United States (40.5%) will have some form of cardiovascular disease.
QuantMD provides software as a service medical
image post-processing technology at the cutting edge for image
registration, quantification and analysis. Coupled with our high speed
imaging and sparse sampling image reconstruction technology consulting
services, we enable faster and more accurate medical image data
acquisition and interpretation from perfusion studies using MRI, SPECT
and Ultrasound imaging modalities.
We represent the cutting edge in non-invasive imaging and
medical quantification for diagnosing cardiac health by providing high quality quantitative analysis of cardiac structure, function and perfusion from contrast enhanced cardiac imaging, identifying
early signs of heart disease long before the patient experiences a major adverse cardiac event. The emphasis of business is on the use of the real-time
non-invasive cardiac diagnostics capabilities of MRI and other popular imaging
modalities to definitively identify early symptoms of heart disease long before
the patient actually experiences a heart attack, thereby facilitating
early patient healthcare and ensuring greater effectiveness of treatment.
The founding members and key IP contributors of QuantMD are Prahlad G. Menon, MS, PhD '13, Mark Doyle, Ph.D, and Robert W.W. Biederman, MD, from Allegheny General Hospital, Pittsburgh, PA (USA) and David Schwartzman, MD, from University of Pittsburgh Medical Center. To learn more about our group, please visit our team page.
If you are interested in knowing more about QuantMD you may reach us at +1 (412) 259-3031 or check out our latest technologies in the works or being serviced outside the US in the picture slideshow at www.justcallharry.com. We are currently seeking corporate collaboration and partnering and look forward to hearing from you. You can also contact us via e-mail at : firstname.lastname@example.org
Click here for a detailed schematic overview of QuantMD's technology, its potential impact and our implementation strategy.
At present, our web site is still under
construction and doesn't present the applications of our technologies to surgical planning and real-time interventional guidance, which we currently service in India and are conducting animal trials on in Pittsburgh, PA (USA). But for more information in this regard, please contact us. We are making an effort to present you with our entire spectrum of services as soon as possible. If you are a web-developer interested in helping us in this regard, certainly get in touch with us through www.justcallharry.com
Read about the Carnegie Mellon lab where all this magic happens - The MeDCaVE.